ARTICLE | Distillery Therapeutics
Infectious disease
March 1, 2018 2:35 PM UTC
Human sample and mouse studies suggest rocaglate-based inhibitors of P. falciparum eIF4A could help treat cerebral malaria. In vitro, a rocaglate analog that inhibits mammalian eIF4A decreased P. falc...
BCIQ Company Profiles
BCIQ Target Profiles
Plasmodium falciparum eukaryotic initiation factor 4A (P. falciparum eIF4A)